April 14, 2021 -- ImmunoScape has completed a financing round that raised $14 million to enlarge its Singapore-based team, further its expansion into the U.S., and scale up its new San Diego laboratory.
The company will also continue advancing the capabilities of its deep immunomics platform, which enables the characterization of a patient's immunome at ultrahigh resolution. The funds will support increasing the capacity for in-house research and development activities. ImmunoScape plans to expand its biopharmaceutical and academic partnerships in drug development efforts within immuno-oncology, infectious diseases, and autoimmune diseases.
The deep immunomics platform integrates single-cell analysis technologies and bioinformatics for both drug discovery and high-dimensional immune profiling.
This financing round was led by existing investors Anzu Partners, University of Tokyo Edge Capital Partners (UTEC), and new investor EDBI, an investment arm of the Economic Development Board of Singapore. In the past year, ImmunoScape has raised a total of $25 million.